2B4 - A potential target in Staphylococcus aureus associated allergic inflammation.

2B4 Eosinophils SEB induced peritonitis Staphylococcus enterotoxin B (SEB) sCD48

Journal

Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202

Informations de publication

Date de publication:
16 Aug 2023
Historique:
received: 29 01 2023
medline: 16 8 2023
pubmed: 16 8 2023
entrez: 16 8 2023
Statut: aheadofprint

Résumé

Staphylococcus aureus (SA) and its exotoxins activate eosinophils (Eos) and mast cells (MCs) via CD48, a GPI-anchored receptor belonging to the Signaling Lymphocytes Activation Molecules (SLAM) family. 2B4 (CD244), an immuno-regulatory transmembrane receptor also belonging to the SLAM family, is the high affinity ligand for CD48. 2B4 is expressed on several leukocytes including NK cells, T cells, basophils, monocytes, dendritic cells (DCs) and Eos. In the Eos and MCs crosstalk carried out by physical and soluble interactions (named the 'Allergic Effector Unit', AEU), 2B4-CD48 binding plays a central role. As CD48 and 2B4 share some structural characteristics and SA colonization accompanies most of the allergic diseases, we hypothesized that SA exotoxins (e.g., Staphylococcus enterotoxin B, SEB), can also bind and activate 2B4 and thereby possibly further aggravate inflammation. To check our hypothesis, we employed in vitro, in- silico and in vivo methods. By Enzyme-linked immunosorbent assay (ELISA), flow cytometry (FC), fluorescence microscopy and microscale thermophoresis (MST), we have shown that SEB can bind specifically to 2B4. By Eos short- and long-term activation assays, we confirmed the functionality of the SEB-2B4 interaction. Using computational modeling, we identified possible SEB-binding sites on human and mouse 2B4. Finally, in vivo, in a SEB-induced peritonitis model, 2B4-KO mice showed a significant reduction of inflammatory features compared to WT mice. Altogether, the results of this study confirm that 2B4 is an important receptor in SEB-mediated inflammation and therefore a role is suggested for 2B4 in SA associated inflammatory conditions.

Identifiants

pubmed: 37583293
pii: 7242641
doi: 10.1093/cei/uxad089
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Pratibha Gaur (P)

Pharmacology & Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Mansour Seaf (M)

Pharmacology & Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Nirit Trabelsi (N)

Department of Microbiology & Molecular Genetics, IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Orly Marcu (O)

Department of Microbiology & Molecular Genetics, IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Daria Gafarov (D)

Pharmacology & Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Ora Schueler-Furman (O)

Department of Microbiology & Molecular Genetics, IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Ofer Mandelboim (O)

The Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, IMRIC, Jerusalem, Israel.

Micha Ben-Zimra (M)

Pharmacology & Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Francesca Levi-Schaffer (F)

Pharmacology & Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

Classifications MeSH